Get started
Author

Shingo Miyamoto

Observed institution: Japanese Red Cross Medical Center
ORCID: 0000-0001-7094-8559
Observed ORCID: 0000-0001-7094-8559
OpenAlex ID: A5009923716
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2022 · Akira Sugimoto, Shingo Matsumoto, et al. · Clinical Cancer Research · 76
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
2024 · Masanobu Okahisa, Hibiki Udagawa, et al. · Lung Cancer · 13
PDF
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al. · 1
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025 · Akira Sugimoto, Shingo Matsumoto, et al.
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
2025 · Yuji Uehara, Hiroki Izumi, et al. · Lung Cancer
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Works count: 13
Citation count: 90
H-index: 2
I10-index: 2
Year
Topic
Type